ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0042

Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis
Abstract Number: 0043

Single-cell and Spatial Transcriptomic Profiling of Muscle Reveals Inflammatory Mechanisms in Anti-glycyl tRNA Synthetase Syndrome
Abstract Number: 0044

DNA Methylation Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis Highlight Divergent Immune Pathways
Abstract Number: 0045

Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
Abstract Number: 0046

Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease
Abstract Number: 0047

Monocyte Transcriptomic Signatures Uncover Potential Pathogenic Mechanisms of the APOL1 High Risk Genotype (HRG)
Abstract Number: 0048

Integrative Spatial Proteomics and Single-Cell RNA Sequencing Unveil Molecular Complexity in Rheumatoid Arthritis for Novel Therapeutic Targeting
Abstract Number: 0049

Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
Abstract Number: 0050

TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
Abstract Number: 0051

Spp1+ Macrophages Are Specifically Enriched in Arthritic Joints and Associated with Abnormal Bone Metabolism in Collagen-Induced Arthritis Mice
Abstract Number: 0052

Profiling of MT-3534, a Humanized Monoclonal Antibody Targeting Peptidylarginine Deiminase 4, as a Candidate Drug for the Treatment of RA
Abstract Number: 0053

The Integrin Inhibitor Cilengitide Targets CCN1-Mediated Angiogenesis and Reduces Disease Severity in a Preclinical Rheumatoid Arthritis Model
Abstract Number: 0054

Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice
Abstract Number: 0055

TCR Signaling Thresholds Govern Anergy and Tolerance in ZAP70 Hypomorphic Models of Autoimmune Arthritis
Abstract Number: 0056

Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model

« Previous Page
1
…
4
5
6
7
8
…
182
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].